Regeneron stock gains 1.67 percent as legal risk eases
Published on 09/22/2026 at 17:52 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Regeneron Pharmaceuticals, Inc. (ISIN US75886F1075) closed at USD 797.99 on Nasdaq on September 21, 2026, up 1.67 percent from the prior close of USD 784.85. The gain followed a court ruling that reduced a legal overhang tied to allegations involving the company's Eylea franchise.
Legal ruling supports the shares
According to Law360 on September 21, 2026, a judge ruled that investors could not use a separate False Claims Act case to support allegations in a proposed securities class action against Regeneron and several executives. The decision concerned claims about the company's revenue prospects for its vision-loss drug and alleged reimbursement practices.
The market reaction was visible in the numbers: the stock gained USD 13.14 between the September 20 close of USD 784.85 and the September 21 close of USD 797.99. The ruling does not remove commercial or regulatory risks surrounding Eylea, but it changes the immediate litigation backdrop for shareholders.
Quarterly earnings set the benchmark
Regeneron's latest listed earnings entry was for Q2 2026, reported on July 30, 2026. MarketBeat showed reported EPS of USD 10.16 for that quarter, although the indexed result did not provide the corresponding actual revenue figure in the available extract.
That earnings date also gives investors a concrete comparison point for valuation. Yahoo Finance reported a market capitalization of USD 79.7 billion and a forward price-to-earnings multiple of 12.9 on September 22, 2026. The combination places the legal headline beside a current large-cap valuation rather than an isolated one-day price move.
Valuation remains the key counterweight
According to Yahoo Finance on September 22, 2026, Regeneron has recorded average annual revenue growth of 4.6 percent over the last five years. That historical growth rate is materially lower than the pace associated with many smaller biotechnology companies, making product concentration and pipeline execution important valuation variables.
The next market checkpoint is therefore not only the legal outcome but also whether future reports can support the current earnings base. Q2 2026 EPS of USD 10.16, the September 21 closing price of USD 797.99 and the USD 79.7 billion market capitalization provide the dated reference points available to investors.
Regeneron stock closes at USD 797.99
Regeneron stock closed at USD 797.99 on Nasdaq on September 21, 2026, compared with USD 784.85 previously. The 1.67 percent daily gain followed the September 21 legal ruling and leaves the stock anchored to a USD 79.7 billion market capitalization as of September 22, 2026.
Regeneron Pharmaceuticals stock data
- Company: Regeneron Pharmaceuticals, Inc.
- ISIN: US75886F1075
- Ticker: REGN
- Trading venue: Nasdaq
- Price as of September 21, 2026: USD 797.99
- Market capitalization: USD 79.7 billion as of September 22, 2026
- Sector / Industry: Health Care / Biotechnology
- Index membership: S&P 500
